To evaluate the
antihypertensive effects of
lisinopril, a renally excreted
angiotensin-converting enzyme inhibitor, we assessed supervised administration of the
drug after
hemodialysis (HD) three times weekly. Blood pressure (BP) was assessed by interdialytic 44-hour ambulatory BP (ABP) monitoring, and endocrine responses were assessed by plasma
renin activity (PRA) before and after dialysis.
Lisinopril dose was titrated at biweekly intervals. If this was not effective after full titration (
lisinopril to 40 mg three times weekly), ultrafiltration was added to reduce dry weight. The primary outcome variable was change in BP from the end of the run-in period to the end of the study. No change in mean ABP was noted during run-in. However, mean 44-hour ABP decreased from 149 +/- 14 (SD)/84 +/- 9 to 127 +/- 16/73 +/- 9 mm Hg, a decrease of 22/11 mm Hg (P < 0.001) at final evaluation. Of 11 patients who completed the trial, only 2 patients had
systolic hypertension (>/=135 mm Hg) and 1 patient had diastolic
hypertension (>/=85 mm Hg) at the final visit. Four patients were administered 10 mg of
lisinopril; 5 patients, 20 mg; and 2 patients, 40 mg; only 1 of these patients required ultrafiltration
therapy. There was a persistent
antihypertensive effect over 44 hours. BP reduction was achieved without an increase in intradialytic symptomatic or asymptomatic hypotensive episodes. PRA increased in response to dialysis, as well as
lisinopril. In conclusion, supervised
lisinopril therapy is effective in controlling
hypertension in chronic HD patients. This may be related to blockade of
angiotensin II generation by kidneys despite the loss of excretory function.